克雷森特生物制药 CBIO
$13.54 +$0.60 (+4.64%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $13.54 0.00%
开盘$12.84
昨收$12.94
当日区间$12.75 – $13.91
成交量137.8K
市值$502.93M
市盈率（TTM）–
股息率–
基本面
最新报告季度：Q2, ended Jun 2026
营收$0.00
营业利润-$26.36M-25.4% YoY
净利润-$24.84M-14.0% YoY
摊薄每股收益-$0.74+85.0% YoY
自由现金流-$19.48M-17.7% YoY
经营现金流-$19.46M
营收，近7个季度
净利润，近7个季度
各季度摊薄每股收益
各季度自由现金流
盈利能力与资产负债表
营业利润率-1,417.7%
净利率-1,389.6%
净资产收益率-112.1%
资产收益率-97.1%
投入资本回报率-114.6%
流动比率9.66
负债/资产比率10.7%
现金及投资$171.59M
总负债$966,000.00
净现金（净负债）$170.63M
资产负债表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 ANNUAL | 2025 Q3 |
|---|---|---|---|---|---|
| -优先股 | $4.00M | $4.00M | $4.00M | $4.00M | $4.00M |
| 流动负债合计 | $18.54M | $14.19M | $36.07M | $36.07M | $20.30M |
| 负债合计 | $19.50M | $15.28M | $37.28M | $37.28M | $21.63M |
| 其他非流动资产 | $1.61M | $1.27M | $1.32M | $1.32M | $1.36M |
| -固定资产原值 | $2.15M | $2.30M | $2.32M | $2.32M | $2.35M |
| 固定资产净值 | $2.15M | $2.30M | $2.32M | $2.32M | $2.35M |
| 其他流动资产 | $2.17M | $1.37M | $1.28M | $1.28M | $1.30M |
| 预付资产 | $5.24M | $5.03M | $4.19M | $4.19M | – |
| -应收账款 | $0.00 | $0.00 | $18.00M | $18.00M | – |
| 应收款 | $0.00 | $0.00 | $18.00M | $18.00M | – |
| -现金及现金等价物 | $171.59M | $189.16M | $213.19M | $213.19M | $133.27M |
| 现金及现金等价物与短期投资 | $171.59M | $189.16M | $213.19M | $213.19M | $133.27M |
| 流动资产合计 | $179.01M | $195.56M | $236.66M | $236.66M | $134.56M |
| 总资产 | $182.76M | $199.13M | $240.29M | $240.29M | $138.27M |
| 应付款 | $2.54M | $1.19M | $18.14M | $18.14M | $8.83M |
| -应付账款 | $2.54M | $1.19M | $10.00M | $10.00M | $2.56M |
| -应付税款合计 | $0.00 | $0.00 | $8.00M | $8.00M | – |
| -普通股 | $28,000.00 | $28,000.00 | $28,000.00 | $28,000.00 | $14,000.00 |
| 股本 | $4.03M | $4.03M | $4.03M | $4.03M | $4.01M |
| 股东权益 | $163.26M | $183.85M | $203.01M | $203.01M | $116.64M |
| 股东权益合计 | $163.26M | $183.85M | $203.01M | $203.01M | $116.64M |
| -长期融资租赁负债 | $966,000.00 | $1.09M | $1.21M | $1.21M | $1.32M |
| 长期债务及融资租赁负债 | $966,000.00 | $1.09M | $1.21M | $1.21M | $1.32M |
| 非流动负债合计 | $966,000.00 | $1.09M | $1.21M | $1.21M | $1.32M |
| 其他流动负债 | $5.00M | $5.00M | $5.00M | $5.00M | $2.09M |
| 一年内递延负债 | $3.12M | $3.12M | $4.16M | $4.16M | – |
| -一年内到期融资租赁负债 | $471,000.00 | $453,000.00 | $435,000.00 | $435,000.00 | $417,000.00 |
| 一年内应计费用 | $4.04M | $2.62M | $3.22M | $3.22M | $6.21M |
| -一年内应付关联方款项 | $0.00 | $0.00 | $140,000.00 | $140,000.00 | $6.27M |
| 资本公积 | $379.16M | $374.91M | $370.79M | $370.79M | $192.04M |
| 非流动资产合计 | $3.75M | $3.57M | $3.64M | $3.64M | $3.71M |
| 短期债务及融资租赁负债 | $471,000.00 | $453,000.00 | $435,000.00 | $435,000.00 | $417,000.00 |
| 留存收益 | -$219.93M | -$195.09M | -$171.81M | -$171.81M | -$79.41M |
| 可转换优先证券 | – | – | $0.00 | $0.00 | $0.00 |
现金流量表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| -预付资产变动 | -$1.01M | -$937,000.00 | -$5.02M | -$4.17M | $284,000.00 |
| -应付账款及应计费用变动 | $4.47M | -$5.91M | $363,000.00 | -$6.17M | $4.58M |
| -其他流动负债变动 | -$106,000.00 | -$101,000.00 | $4.96M | $4.90M | $46,000.00 |
| -其他营运资金变动 | -$339,000.00 | -$982,000.00 | $4.32M | $4.19M | $47,000.00 |
| 投资活动现金流净额 | $1.76M | -$8.15M | -$72.92M | -$72.19M | -$586,000.00 |
| 持续经营投资活动现金流净额 | $1.76M | -$8.15M | -$72.92M | -$72.19M | -$586,000.00 |
| 固定资产购置及出售净额 | -$13,000.00 | -$147,000.00 | -$919,000.00 | -$193,000.00 | -$586,000.00 |
| 无形资产购置及出售净额 | $0.00 | -$8.00M | -$72.00M | – | – |
| 筹资活动现金流 | $136,000.00 | -$6.95M | $322.98M | $178.86M | -$1.25M |
| 持续经营筹资活动现金流净额 | $136,000.00 | -$6.95M | $322.98M | $178.86M | -$1.25M |
| 股票期权行使所得 | $280,000.00 | $0.00 | $5,000.00 | $177,000.00 | -$177,000.00 |
| 其他筹资费用净额 | -$144,000.00 | -$6.95M | $1.27M | $0.00 | $0.00 |
| 期末现金余额 | $171.70M | $189.27M | $213.30M | $213.30M | $133.37M |
| 现金净变动 | -$17.57M | -$24.03M | $178.53M | $79.93M | -$19.38M |
| 期初现金余额 | $189.27M | $213.30M | $34.77M | $133.37M | $152.75M |
| 自由现金流 | -$19.48M | -$17.08M | -$144.45M | -$98.93M | -$18.13M |
| 经营活动现金流 | -$19.46M | -$8.94M | -$71.53M | -$26.74M | -$17.54M |
| 持续经营经营活动现金流净额 | -$19.46M | -$8.94M | -$71.53M | -$26.74M | -$17.54M |
| 持续经营净利润 | -$24.84M | -$23.28M | -$153.94M | -$92.40M | -$24.61M |
| 折旧、折耗与摊销 | $66,000.00 | $64,000.00 | $84,000.00 | $54,000.00 | $28,000.00 |
| 其他非现金项目 | $101,000.00 | $97,000.00 | $82.40M | $80.10M | $94,000.00 |
| 营运资金变动 | $3.01M | $10.07M | -$13.37M | -$19.24M | $4.96M |
| -应收款变动 | $0.00 | $18.00M | -$18.00M | – | – |
| 优先股发行净额 | – | – | $0.00 | – | – |
| 普通股发行净额 | – | – | $321.71M | $178.68M | -$1.08M |
| 债务发行及偿还净额 | – | – | $0.00 | – | – |
利润表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 销售及管理费用 | $8.74M | $7.87M | $25.39M | $7.31M | $5.54M |
| 研发费用 | $19.39M | $17.90M | $138.09M | $95.03M | $20.35M |
| 其他营业费用 | -$1.77M | – | – | – | – |
| 营业利润 | -$26.36M | -$24.73M | -$152.63M | -$91.49M | -$25.89M |
| 非经营性利息净收入（支出） | $1.53M | $1.45M | $690,000.00 | $1.10M | $1.28M |
| 非经营性利息收入 | $1.53M | $1.45M | $2.88M | $1.10M | $1.28M |
| 非经营性利息支出 | $0.00 | $0.00 | $2.19M | $0.00 | $0.00 |
| 税前利润 | -$24.84M | -$23.28M | -$151.94M | -$90.40M | -$24.61M |
| 净利润 | -$24.84M | -$23.28M | -$153.94M | -$92.40M | -$24.61M |
| 持续经营利润 | -$24.84M | -$23.28M | -$153.94M | -$92.40M | -$24.61M |
| 归属母公司净利润 | -$24.84M | -$23.28M | -$153.94M | -$92.40M | -$24.61M |
| 归属普通股股东净利润 | -$24.84M | -$23.28M | -$153.94M | -$92.40M | -$24.61M |
| 基本每股收益 | -$0.74 | -$0.70 | -$12.81 | -$4.01 | -$1.27 |
| 营业费用 | $26.36M | $25.77M | $163.48M | $102.34M | $25.89M |
| 营业总收入 | $0.00 | $1.04M | $10.84M | $10.84M | $0.00 |
| 报告营业总收入 | $0.00 | $1.04M | $10.84M | – | – |
| 摊薄每股收益 | -$0.74 | -$0.70 | -$12.81 | -$4.01 | -$1.27 |
| -管理费用 | $8.74M | $7.87M | $25.39M | $7.31M | $5.54M |
| 税费 | – | – | $2.00M | – | – |
暂无评论——快来第一个聊聊 CBIO。
登录后参与讨论。